Therefore, EGFR has become an important target for therapeutic interventions, and drugs that inhibit EGFR signaling, such as tyrosine kinase inhibitors and monoclonal antibodies, have been developed for the treatment of certain cancers. This evidence concerns the gene EGFR and cancer.